Oncocyte (NASDAQ:IMDX) Posts Earnings Results

Oncocyte (NASDAQ:IMDX) posted its quarterly earnings results on Monday. The company reported ($0.23) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.24 million during the quarter.

Oncocyte Stock Performance

Shares of IMDX stock traded down $0.06 on Monday, hitting $4.77. The company had a trading volume of 73,257 shares, compared to its average volume of 228,315. Oncocyte has a twelve month low of $2.33 and a twelve month high of $8.51. The firm has a market cap of $154.02 million, a P/E ratio of -3.22 and a beta of 1.79. The stock’s 50-day moving average is $5.24 and its two-hundred day moving average is $5.15.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oncocyte in a research report on Wednesday, June 24th. Wall Street Zen upgraded shares of Oncocyte from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.